Sienna Biopharmaceuticals Inc (SNNA):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Sienna Biopharmaceuticals Inc (SNNA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8169
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:41
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Sienna Biopharmaceuticals Inc (Sienna Biopharmaceuticals) is a clinical-stage biopharmaceutical company that develops and commercializes topical products in medical dermatology and aesthetics. Through its topical photoparticle therapy platform, the company advanced its product SNA-001, into pivotal clinical trials for both acne vulgaris and the reduction of unwanted light-pigmented hair. SNA-120, the company’s lead candidate from topical by design platform (TBD), currently in Phase 2b clinical development, is an inhibitor of tropomyosin receptor kinase A intended for the treatment of pruritus and psoriasis. Its second TBD product candidate, SNA-125, is a dual JAK3/TrkA inhibitor being developed for the treatment of atopic dermatitis, psoriasis and pruritus. Sienna Biopharmaceuticals is headquartered in Westlake Village, California, the US.

Sienna Biopharmaceuticals Inc (SNNA) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Sienna Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Sienna Biopharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Sienna Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Sienna Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Sienna Biopharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10
Sienna Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Sienna Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Sienna Biopharma Raises USD40 million in Series B Financing 12
Sienna Biopharma Raises Additional USD12 Million in Series A Financing 14
Sienna Biopharma Raises USD34 Million in Series A Financing 15
Sienna Biopharma Raises USD18.4 Million in Financing 16
Equity Offering 17
Sienna Biopharma Plans to Raise up to USD75 Million in Public Offering of Shares 17
Sienna Biopharma Raises USD74.7 Million in IPO 18
Sienna Biopharma Raises USD0.6 Million in Private Placement of Shares 20
Acquisition 21
Sienna Biopharmaceuticals Acquires Creabilis 21
Sienna Biopharmaceuticals Inc – Key Competitors 22
Sienna Biopharmaceuticals Inc – Key Employees 23
Sienna Biopharmaceuticals Inc – Locations And Subsidiaries 24
Head Office 24
Other Locations & Subsidiaries 24
Recent Developments 25
Financial Announcements 25
Aug 09, 2018: Sienna Biopharmaceuticals reports second quarter 2018 financial results 25
May 14, 2018: Sienna Biopharmaceuticals Reports First Quarter 2018 Financial Results 27
Mar 15, 2018: Sienna Biopharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results 28
Nov 09, 2017: Sienna Biopharmaceuticals Reports Third Quarter 2017 Financial Results 30
Sep 07, 2017: Sienna Biopharmaceuticals Reports Second Quarter 2017 Financial Results 31
Corporate Communications 32
Aug 02, 2018: Sienna Biopharmaceuticals Appoints Finance Veteran, James M. Hindman, to Board of Directors 32
Mar 22, 2018: Sienna Biopharmaceuticals Appoints Caroline Van Hove as Chief Commercial Officer 33
Mar 21, 2018: Sienna Biopharmaceuticals Appoints John W. Smither as Chief Financial Officer 34
Jun 14, 2017: Sienna Biopharmaceuticals Appoints Erle Mast, Former CFO and Co-Founder of Clovis Oncology, to Board of Directors 35
Mar 24, 2017: Richard Peterson Joins Sienna Biopharmaceuticals As Chief Financial Officer 36
Legal and Regulatory 37
May 07, 2018: Sebacia Announces Favorable Ruling by U.S. Court of Appeals for the Federal Circuit Regarding Patent Interference Proceedings with Sienna Biopharmaceuticals 37
Product News 38
03/12/2018: Sienna Biopharmaceuticals Announces First Patient Dosed in Proof-of-Concept Trial of Topical by Design JAK Inhibitor SNA-125 for Atopic Dermatitis 38
02/14/2018: Sienna Biopharmaceuticals Announces First Patient Dosed in First-in-Human Trial of Topical SNA-125 39
Clinical Trials 40
Oct 24, 2017: Sienna Biopharmaceuticals Announces First Patient Dosed in Phase 2b Trial of Topical SNA-120 40
Appendix 41
Methodology 41
About GlobalData 41
Contact Us 41
Disclaimer 41

List of Tables
Sienna Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Sienna Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Sienna Biopharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Sienna Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Sienna Biopharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Sienna Biopharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10
Sienna Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Sienna Biopharma Raises USD40 million in Series B Financing 12
Sienna Biopharma Raises Additional USD12 Million in Series A Financing 14
Sienna Biopharma Raises USD34 Million in Series A Financing 15
Sienna Biopharma Raises USD18.4 Million in Financing 16
Sienna Biopharma Plans to Raise up to USD75 Million in Public Offering of Shares 17
Sienna Biopharma Raises USD74.7 Million in IPO 18
Sienna Biopharma Raises USD0.6 Million in Private Placement of Shares 20
Sienna Biopharmaceuticals Acquires Creabilis 21
Sienna Biopharmaceuticals Inc, Key Competitors 22
Sienna Biopharmaceuticals Inc, Key Employees 23
Sienna Biopharmaceuticals Inc, Subsidiaries 24

List of Figures
Sienna Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Sienna Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Sienna Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Sienna Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Sienna Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Sienna Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Sienna Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Sienna Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Sienna Biopharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Sienna Biopharmaceuticals Inc (SNNA):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • SBS Transit Ltd.:企業の戦略・SWOT・財務情報
    SBS Transit Ltd. - Strategy, SWOT and Corporate Finance Report Summary SBS Transit Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Trimedyne Inc (TMED):企業の戦略的SWOT分析
    Trimedyne Inc (TMED) - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Condor Hospitality Trust Inc:戦略・SWOT・企業財務分析
    Condor Hospitality Trust Inc - Strategy, SWOT and Corporate Finance Report Summary Condor Hospitality Trust Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Novartis AG:企業の戦略・SWOT・財務情報
    Novartis AG - Strategy, SWOT and Corporate Finance Report Summary Novartis AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Affinity Water Ltd:企業の戦略的SWOT分析
    Affinity Water Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • Bangladesh Power Development Board:企業の戦略的SWOT分析
    Bangladesh Power Development Board - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Exxon Mobil Corporation (XOM)-石油・ガス分野:企業M&A・提携分析
    Summary Exxon Mobil Corporation (ExxonMobil) is an integrated oil and gas company that explores for and produces crude oil and natural gas; manufactures petroleum products; transports and sells crude oil and petroleum products; and markets natural gas and natural gas liquids. It is a major manufactu …
  • Hanmi Pharmaceuticals Co Ltd (128940):企業の財務・戦略的SWOT分析
    Hanmi Pharmaceuticals Co Ltd (128940) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • Eversource Energy (ES)-エネルギー分野:企業M&A・提携分析
    Summary Eversource Energy (Eversource) is a utility holding company which operates energy delivery business through its subsidiaries. It transmits and distributes electricity and natural gas. The company sources electricity from its facilities, long-term power supply agreements, and competitive ener …
  • Companhia Energetica de Minas Gerais – CEMIG:企業のM&A・事業提携・投資動向
    Companhia Energetica de Minas Gerais - CEMIG - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Companhia Energetica de Minas Gerais - CEMIG Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, d …
  • The Western Union Company:企業のM&A・事業提携・投資動向
    The Western Union Company - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's The Western Union Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisi …
  • Serco Group plc (SRP):企業の財務・戦略的SWOT分析
    Serco Group plc (SRP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Yasuhara Chemical Co Ltd (4957):企業の財務・戦略的SWOT分析
    Yasuhara Chemical Co Ltd (4957) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Amerisafe Inc:企業の戦略・SWOT・財務分析
    Amerisafe Inc - Strategy, SWOT and Corporate Finance Report Summary Amerisafe Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Werner Enterprises, Inc.:企業の戦略・SWOT・財務情報
    Werner Enterprises, Inc. - Strategy, SWOT and Corporate Finance Report Summary Werner Enterprises, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Five Prime Therapeutics Inc (FPRX):製薬・医療:M&Aディール及び事業提携情報
    Summary Five Prime Therapeutics Inc (Five Prime) is a clinical state biopharmaceutical company focusing on the research and development of novel treatments for cancer and inflammatory disorders. The company’s developmental pipeline is based on the discovery platform and library of therapeutic protei …
  • Epigenomics AG (ECX):医療機器:M&Aディール及び事業提携情報
    Summary Epigenomics AG (Epigenomics) is a molecular diagnostics company which develops and commercializes in-vitro diagnostic (IVD) tests for screening, early detection and diagnosis of cancer. Its lead product, Epi proColon is a blood-based test for rapid detection of colorectal cancer; and Epi pro …
  • Macrogen Inc (038290):企業の財務・戦略的SWOT分析
    Macrogen Inc (038290) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Hydra Biosciences Inc-製薬・医療分野:企業M&A・提携分析
    Summary Hydra Biosciences Inc (Hydra) is a biopharmaceutical company that develops novel drugs. The company’s pipeline candidate HX-100 is developed to treat diabetic neuropathy and allergic asthma. It offers other drugs for the therapeutic areas including inflammation, pain, renal, anxiety and pulm …
  • Goodfellow Inc (GDL):企業の財務・戦略的SWOT分析
    Goodfellow Inc (GDL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆